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Abstract
Cancer is viewed as a multistep process whereby a normal cell is transformed into a
cancer cell through the acquisition of mutations. We reduce the complexities of cancer
progression to a simple set of underlying rules that govern the transformation of normal
cells to malignant cells. In doing so, we derive an ordinary differential equation model
that explores how the balance of angiogenesis, cell death rates, genetic instability, and
replication rates give rise to different kinetics in the development of cancer. The key
predictions of the model are that cancer develops fastest through a particular ordering of
mutations and that mutations in genes that maintain genomic integrity would be the most
deleterious type of mutations to inherit. In addition, we perform a sensitivity analysis
on the parameters included in the model to determine the probable contribution of each.
This paper presents a novel approach to viewing the genetic basis of cancer from a systems
biology perspective and provides the groundwork for other models that can be directly tied
to clinical and molecular data.
Keywords: cancer; oncogenesis; genetic instability; multistep transformation; ordinary
differential equation model
1 Introduction
The standard perspective on cancer progression is that it is a form of somatic evolution where certain mutations
give one cell a selective growth advantage (Cahill et al., 1999). Oncogenesis is thought to require several indepen-
dent, rare mutation events to occur in the lineage of one cell (Nowell, 1976). Kinetic analyses have shown that four
to six rate-limiting stochastic mutational events are required for the formation of a tumor (Armitage and Doll,
1954; Renan, 1993). Hanahan and Weinberg (2000) proposed the following six hallmark capabilities that a nor-
mal cell must acquire to become a cancer cell: (i) self-sufficiency in growth signals, (ii) insensitivity to anti-growth
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signals, (iii) evasion of apoptosis, (iv) limitless replicative potential, (v) sustained angiogenesis, and (vi) tissue
invasion and metastasis. They define genetic instability as an “enabling characteristic” that facilitates the ac-
quisition of other mutations due to defects in DNA repair processes. We reduce these characteristics to the
following four: angiogenesis (A), immortality, including evasion of cell death (D), genetic instability, a function
of mutation rates (G), and increased replication rate (R). We consider invasion and metastasis (M) as a final step
that allows the spread of a localized tumor. In line with the views of Hanahan and Weinberg (2000), we foresee
cancer research developing into a logical science where the molecular and clinical complexities of the disease will
be understood in terms of a few underlying principles. We therefore explore the multistep progression to cancer
with an ordinary differential equation (ODE) model which, despite the apparent complexity of the equations, is
based on basic principles and a minimal set of parameters.
2 Structure and parameters of the model
Although the model applies to the process of oncogenesis in general, the parameters are loosely based on breast
cancer data. We consider the following cell populations: a population of 108 normal cells (N), cells which have
acquired the ability to induce angiogenesis (A), cells with mutations which allow them to avoid death (D), cells
with mutations that lead to genetic instability (G), cells with mutations which increase their replication rate
(R), and cells with two or more of these mutations. Cell populations that have acquired two or three mutations
are denoted by listing the mutations together in alphabetical order (state DRA would be listed as state ADR,
for example). We label a cell which has acquired all four mutations a primary tumor cell (T ). Although our
model only addresses development of a primary tumor in genetic detail, we allow a primary tumor cell that has
acquired the capability to invade and metastasize to become a metastatic cell (M).
The spontaneous mutation rate in human cells has been estimated to be in the range of 10−7 to 10−6 mu-
tations/gene/cell division (Jackson and Loeb, 1998). We assume a spontaneous mutation rate of k1 = 10
−7
mutations/gene/cell division. The loss of DNA repair genes can increase the mutation rate by a factor ranging
from 101 to 104 (Tomlinson et al., 1996). We assume that the mutation rate after a genetic instability mutation
increases 1000-fold to k2 = 10
−4 mutations/gene/cell division. Successful invasion and metastasis depend upon
acquisition of the other hallmark capabilities, as well as several new capabilities (Hanahan and Weinberg, 2000).
To simplify the model, we do not address the multistep progression of a tumor cell to a metastatic cell, and
instead consider this complex process as one step. It has been estimated that the rate of successful metastasis
is in the range of 10−9 to 10−7 per cell division (Luebeck and Moolgavkar, 2002), and so we use a conservative
estimate of k3 = 10
−9 for the transition from a primary tumor cell to a metastatic cell.
A tumor cannot grow past about 106 cells without angiogenesis supplying blood to the tumor (Folkman, 1990).
We thus cap the size of the tumor at 106 cells until at least 10% of the population of non-normal, non-metastatic
cells has acquired a mutation in an A gene. This accounts for the fact that only a fraction of the cells in
a tumor need to send angiogenesis signals in order to develop an adequate blood supply for the tumor. In
addition, populations of non-normal, non-metastatic cells are always capped by a lethal tumor burden limit of
1013 cells (Friberg and Mattson, 1997), irrespective of the angiogenesis cap.
A survey of microarray data published on number of genes up- or down-regulated in various cancers (Amatschek et al.,
2004; Ernst et al., 2002; Nakamura et al., 2004; Zou et al., 2002) led us to estimate that there are approximately
400 genes involved in development of a primary tumor. Dividing by four categories, we assume that there are
approximately 100 genes involved in each of categories A, D, G, and R. To account for the fact that some genes
function in more than one category, we allow double and triple state transitions but reduce the number of genes
involved to the order of 10 and 1, respectively, to reflect the likelihood that a single mutation would affect more
than one category. For example, we assume there are 100 genes involved transitions where only one mutation
is acquired (e.g. N → A, D → DR, AG → AGR, or ADG → ADGR), 10 genes involved in transitions where
two mutations are acquired in one step (e.g. N → AD, G → ADG, or AR → ADGR), and 1 gene involved
in transitions where three mutations are acquired in one step (e.g. N → ADG or G → ADGR). This feature
accounts for a mutational hit in p53, for example, which could take a cell directly from N to DGR, as p53 is
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involved in apoptosis, DNA repair, and cell cycle progression (Vogelstein et al., 2000).
We estimate that the relative contribution to increased net proliferation for mutations in the D and R categories
is 0.7 and 0.3, respectively, an inference made from work by Tomlinson and Bodmer (1995). Using this D:R
ratio of 0.7:0.3, a tumor volume doubling time for breast cancer of 500 days (Friberg and Mattson, 1997), and
a cell division rate for breast cancer of 1/10.00 days−1 (Rew and Wilson, 2000), we calculate (see section 4)
the following: cells without a mutation in an R gene divide every b = 10.00 days, cells with a mutation in an R
gene divide every bR = 9.89 days, the lifetime of cells without a mutation in a D gene is d = 10.00 days, and the
lifetime of cells with a mutation in a D gene is dD = 10.16 days. The birth and death rates are equal for normal
cells and for all cells without a mutation in D or R.
The above information is depicted in a unified fashion in Figure 1 and the parameters appearing in the ODE
model are given in Table 1.
Figure 1. State diagram of the model. Normal cells (N) can acquire mutations which give the cell the capability to induce angiogenesis
(A), mutations which give the cell the capability to avoid death (D), mutations which lead to genetic instability (G), or mutations
which increase the proliferation rate (R). These mutations are acquired at rate k1. After a mutation in G, the mutation rate
increases to k2. Cells with one mutation go on to acquire two, three, and four mutations, denoted by listing the mutations together
in alphabetical order for the cases of two and three mutations. When a cell has acquired all four mutations, it becomes a primary
tumor cell (T ). Finally, tumor cells become metastatic cells (M) at rate k3. Double and triple state transitions are also allowed, as
detailed in the text, but are not shown in this diagram for simplification. Cell birth rates (1/b) and cell death rates (1/d) have units
days−1.
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Table 1. Parameters appearing in the ODE model.
Characteristic Parameter Value Reference
Mutation rate without a G mutation k1 10−7 mut./gene/cell div. (Jackson and Loeb, 1998)
Mutation rate with a G mutation k2 10−4 mut./gene/cell div. (Tomlinson et al., 1996)
Metastasis rate k3 10−9 /cell division (Luebeck and Moolgavkar, 2002)
Cell division rate without an R mutation 1/b 1/10.00 days−1 (Rew and Wilson, 2000)
Cell division rate with an R mutation 1/bR 1/9.89 days
−1 see section 4
Cell death rate without a D mutation 1/d 1/10.00 days−1 (Rew and Wilson, 2000)
Cell death rate with a D mutation 1/dD 1/10.16 days
−1 see section 4
Cap when ≤ 10% of cells have A 106 cells (Folkman, 1990)
Lethal tumor burden cap on non-N , non-M cells 1013 cells (Friberg and Mattson, 1997)
In the next section, we present an ODE model that will be used to explore the following areas:
1. The kinetics of various paths to cancer.
2. The effect of inherited mutations on cancer development.
3. A sensitivity analysis of variations in the parameters.
3 Construction of the ODE model
Based on the basic rules outlined in the state diagram in Figure 1, we construct 17 ODEs to model a heterogeneous
population of cells undergoing the multistep process of tumorigenesis. Each equation represents one of the 17
populations of cells depicted in the state diagram and has the following format: the population of cells in a
state is increased by cells gaining mutations and entering that state from previous states, is increased by cells
replicating and remaining in that state, and is decreased by cells gaining new mutations and leaving that state
for a new state. The populations are capped by two logistic terms, as detailed below.
We condense the ODEs into vector format as follows:
dy
dt
=


(
diag
(
diag
(
yTk
)T
b
)
M+ diag
(
(b− d)
T
y
))
S
(
1−
P
NM
1013
)
+mm, no angiogenesis cap,(
diag
(
diag
(
yTk
)T
b
)
M+ diag
(
(b− d)
T
y
))
S
(
1−
P
NM
1013
)
×
(
1−
P
NM
106
)
+mm, angiogenesis cap,
(1)
where y is the row vector of cell populations; y1 is the population of normal cells, y2, y3, . . . , y15 are the populations
of cells with single, double, and triple mutations, y16 is the number of primary tumor cells (cells with all four
mutations), and y17 is the number of metastatic cells. Here, diag (·) is the operator which forms the row
vector of the main diagonal of the matrix. The corresponding rate (row) vector is k, with mutation rates ki
(mutations/gene/cell division) corresponding to the mutation rate for element yi in y. The same applies to the
birth rates b (day−1) and death rates d (day−1). The metastasis rate vector is mm =
(
0, 0, . . . , 0, 10−9 × y16
)
+
(1/bR − 1/dD)y17, corresponding to cells leaving y16 for y17 at rate 10
−9, and a doubling of metastatic cells at
rate (1/bR − 1/dD) for 1/bR and 1/dD as given in Table 1. The 17× 17 upper triangular matrix M consists of
elements Mi,j (j 6= i) for the number of genes associated with going from state i to state j, and
Mi,i = −
∑
j 6=i
Mi,j , (2)
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is the main diagonal containing the number of genes for leaving each of the states. S is the 17× 17 matrix
S =


0 0 0 . . . 0
0 1 0 . . . 0
...
. . .
...
0 . . . 1 0
0 . . . 0 0

 (3)
used to apply the cell population caps to the non-normal, non-metastatic cells. Non-normal, non-metastatic cells
are denoted by PNM , where
PNM =
(
16∑
i=2
yi
)
. (4)
The system is capped at 106 cells using a logistic term if < 10% of the non-normal, non-metastatic cells are
in states with angiogenesis mutations, otherwise this term is removed. The populations of non-normal, non-
metastatic cells are also capped by a lethal tumor burden limit of 1013 cells (Friberg and Mattson, 1997), irre-
spective of the angiogenesis cap. The ODEs are solved using the Runge-Kutta method of order 5, with a variable
step size between 1 and 10−5, to guarantee the errors in calculating the populations remain within 10−4.
Below, we have reproduced the normal cell and four single state ODEs from the compact vector form for ease
of comprehension. Note that our equations assume a constant, renewing population of normal cells, since we
assume that cells leaving state N for other states are few enough in number so as not to affect the population of
N cells.
dPN
dt
= 0, (5a)
dPA
dt
=
(
100PNk1
b
−
(3× 100 + 3× 10 + 1)PAk1
b
)(
1−
PNM
106
)(
1−
PNM
1013
)
, (5b)
dPD
dt
=
(
100PNk1
b
+ PD
(
1
b
−
1
dD
)
−
(3× 100 + 3× 10 + 1)PDk1
b
)(
1−
PNM
106
)(
1−
PNM
1013
)
, (5c)
dPG
dt
=
(
100PNk1
b
−
(3× 100 + 3× 10 + 1)PGk2
b
)(
1−
PNM
106
)(
1−
PNM
1013
)
, (5d)
dPR
dt
=
(
100PNk1
b
+ PR
(
1
bR
−
1
d
)
−
(3× 100 + 3× 10 + 1)PRk1
bR
)(
1−
PNM
106
)(
1−
PNM
1013
)
, (5e)
(5f)
...
The equations for the other populations follow the same format and can be derived from the state diagram and
from the vector form of the ODEs. In words, Equation 5c, for example, says that the population of cells with a
mutation in D is increased by normal cells gaining a mutation in one of 100 genes in D at a rate of k1 every b
days. The population is also increased by cells in state D replicating (but not mutating) every b days and dying
every dD days. The population is decreased by cells leaving state D and gaining a single mutation in one of 3
other categories (AD, DG, DR) each with 100 genes, by gaining a double mutation in one of 3 ways (DGR,
ADG, ADR), with 10 genes being involved in each transition, or by gaining a triple mutation to go to state
ADGR with 1 gene being involved in the transition. The logistic term caps the total population of non-normal,
non-metastatic cells at 106 cells. What is not visible in this standard form of the ODEs but is present in the
vector form is the fact that the logistic angiogenesis cap is only imposed when less than 10% of the non-normal,
non-metastatic cells have a mutation in the A category. Finally, populations of non-normal, non-metastatic cells
are always capped by a lethal tumor burden limit of 1013 cells.
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4 Calculation of cell division and cell death rates
In order to calculate the change in cell division and cell death rates for mutations in R and D, we begin with
the assumption that birth and death rates are equal for normal cells, i.e. cell division rate = 1/b = cell death
rate = 1/d = 1/10 days−1.
We use an approximation to the ODEs where we treat the rate of cells entering and leaving the state as negligible
compared with the tumor volume doubling time, since they are several orders of magnitude different. Thus, for
cells with mutations in D but not R, say, we consider
dD
dt
= D
(
1
b
−
1
dD
)
. (6)
Solving this gives D = D0 exp ((1/b− 1/dD) t). A doubling corresponds to 2 = exp ((1/b− 1/dD)TD). Similarly,
for cells with mutations in R and not D, we arrive at R = R0 exp ((1/bR − 1/d) t). Taking the natural logarithm
of both sides leads to Equations 7 and 8,
ln 2
1/bR − 1/d
= TR, (7)
ln 2
1/b− 1/dD
= TD, (8)
where TR is tumor volume doubling time for cells with a mutation in R but not D and equals T +50× 3, where
TD is the tumor volume doubling time for cells with a mutation in D but not R and equals T +50×7, and where
the D : R importance ratio is 0.7 : 0.3. The base tumor volume doubling time is T when the growing tumor
has mutations in both D and R (500 days). The value 50 is chosen to give realistic doubling times for cells with
mutations in D (but not R) and R (but not D), on the upper bound of observed tumor volume doubling times,
where the cells typically have both mutations.
5 Kinetics of various paths to cancer
Given that multiple mutations are necessary to form a tumor, we are interested in whether the specific order
of mutations is important. It is currently believed that the temporal sequence of mutations determines the
propensity of tumor development (Arends, 2000). The extent to which genetic instability (G) determines the
timing of tumorigenesis has been a controversial issue in cancer biology. Some have argued that an increased
premalignant mutation rate (that is, acquiring a mutation in G early) is necessary for tumor development (Loeb,
1991; Rajagopalan et al., 2003). Others have argued that an increased cell division rate, offering more opportu-
nities to accumulate mutations, is sufficient for tumorigenesis (Tomlinson and Bodmer, 1995, 1999; Sieber et al.,
2003). Although the extent to which angiogenesis (A), decreased apoptosis (D), genetic instability (G), and
increased replication rate (R) contribute to the development of cancer depends on the type of cancer involved,
a better general understanding of the kinetics of various paths to cancer can be informative about their relative
importance.
We explore the kinetics of various pathways to cancer by analyzing the dynamics of the different cell populations.
By plotting different sets of cell populations, we are able to identify the individual contribution of each mutation
to the development of cancer. The growing populations of cells plateau at various points in the graphs due to
the imposed 1013 cell population cap. In this model, the fastest pathway for tumor progression starts with a
mutation in D (Figure 2(a)) which increases the population of potential tumor cells. Next, a mutation in R is
acquired, further increasing the population of cells by clonal expansion (Figure 2(b)). After acquiring these two
mutations, the tumor is sufficiently large to be inhibited by the angiogenesis cap imposed by the model. For
this reason, a mutation in the angiogenesis category occurs next in the fastest path (Figure 2(c)). Finally, a
mutation in G follows. Figure 2(d) shows the populations of tumor cells, T , and metastatic cells, M . Although
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the rate k3 = 10
−9 is very low, the large increase in population of T cells guarantees that eventually some cells
successfully metastasize.
Our model predicts that genetic instability is more likely to be a feature of later-stage sporadic tumors, in
accordance with the view of Tomlinson and Bodmer (1999). This is because a mutation in G has no direct
selective advantage, only an indirect advantage through increasing the mutation rates in other genes. Although
genetic instability can aid tumorigenesis, selection and clonal expansion are the main driving force for tumor
progression in this model, a conclusion which has been proposed previously by Sieber et al. (2003).
6 Effect of inherited mutations on cancer development
Here we examine the effect of different inherited mutations on cancer development by varying our initial condi-
tions. Since most inherited cancers are the result of mutations in tumor suppressors (Knudson, 2002), we model
this situation by increasing the rate of transition from a normal cell to the appropriate mutated cell to 10−5
mutations/gene/cell division. This models a case where a person inherits an inactivating mutation in one allele
of the gene. These cells are still functionally “normal” (thus they begin in state N), but the chance of acquiring
the second “hit” and losing functionality of the protein (moving into the mutated state) is much increased.
As expected, inheriting a mutation in a cancer-critical gene decreases the time to cancer onset. The effects of
inheriting a mutation in each category on time to reach 109 primary tumor cells, 1012 primary tumor cells, and
1012 metastatic cells are shown in Figure 3. A tumor volume of 1 cubic centimeter weighs about 1 gram and
represents about 109 cells (Friberg and Mattson, 1997). This tumor size is regarded as relatively small in a clinical
setting and it is at this size that a tumor may give rise to the first symptoms and may first become detectable by
palpation (Friberg and Mattson, 1997). A tumor that weighs about 1 kilogram (1012 cells) is approaching the
lethal tumor burden for a patient (Friberg and Mattson, 1997). The 1012 metastatic cells plotted in Figure 3 are
not necessarily localized to one site in the body; they could represent 1012 cells present in one location or 1011
cells present in each of 10 different locations, for example.
In contrast to the results obtained in 4.1.1 where the increased population of cells caused by mutations in D
and R dominates the fastest path to sporadic cancer, inheriting a mutation in a G gene causes cancer onset at
the earliest age. There is no observable difference between inheriting a mutation in one of the other categories
and inheriting no mutations at all. In the fastest path plots (Figure 2), there is equal probability of acquiring a
mutation in A, D, G or R. D will dominate over G due to the fact that the transition from one state to another
is a function not only of the mutation rates k1 and k2 but also the cell population size. Both D and G are equally
likely to begin with, but since D increases the net cell population very quickly, it soon dominates over the rate
k2 associated with G. Therefore, the fastest path to sporadic cancer is through a mutation in D first.
In comparison, when a mutation in G is inherited, the cell has already surpassed the initial probability hurdle
of acquiring a mutation in G. The rate of subsequent mutation is now 1000-fold higher and once a mutation in
D or R is obtained, the cell population will begin to increase. For this reason, an inherited mutation in G has
the greatest effect. This is consistent with the fact that many inherited cancer syndromes are the result of a
mutation in the G category. These include xeroderma pigmentosum, ataxia telangiectasia, Nijmegen breakage
syndrome, hereditary non-polyposis colorectal cancer, and Bloom syndrome (Sieber et al., 2003).
The time to develop a palpable primary tumor (109 cells) in this model is 16.25 years if no mutations are inherited
(Figure 3). Even taking into account the fact that detection of the tumor would not occur until several years
later (Friberg and Mattson, 1997), this age of cancer onset is significantly earlier than the average age of cancer
onset in the human population (DePinho, 2000). This is an indication of the need for more accurate information
on cell division, cell death, and tumor doubling rates. Importantly, this may also be an indication that acquisition
of mutations in more than four categories is necessary for development of a primary tumor. Adding two more
steps to the multistep model would certainly delay the time to cancer, and would be more in accordance with
the six-step model proposed by Hanahan and Weinberg (2000). Consideration of the role of the immune system
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(a) (b)
(c) (d)
(e)
Figure 2. Fastest path to cancer. (a) Dynamics of cell populations with one type of mutation. (b) Dynamics of cell populations
with two types of mutations. (c) Dynamics of cell populations with three types of mutations. (d) Dynamics of cell populations with
four types of mutations (T ), and those that have metastasized (M). (e) The fastest path to cancer is by acquiring a mutation in D,
then R, then A, then G.
in curbing the growth of a tumor would also slow the time to cancer onset. Our model does not directly consider
this factor, although category D does allow for apoptosis initiated by the immune system. Consideration of these
three factors would allow the model to be more appropriately scaled to the timing of human cancer.
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Figure 3. Inherited mutations in cancer-critical genes. Age at which a person may acquire 109 primary tumor cells, 1012 primary
tumor cells, and 1012 metastatic cells with different inherited mutations. For reference, the case where no mutations are inherited
is also shown (N).
7 Sensitivity analysis of variations in the parameters
In order to determine the relative contributions of the parameters to the model, we vary each parameter listed
in Table 2 while holding all others constant at the default value. The default values chosen are our best estimate
from the literature. Except for D:R importance ratio where we use 0.3:0.7 to determine the effect on the fastest
path, and % A cells needed to remove cap where we test the range from 0% to 100%, the other values are chosen
to be near the upper and lower bounds of the range given in the literature. We assess the contribution of each
by examining their effect on time to reach 1012 M cells and on the fastest pathway to cancer in Table 2.
The most salient result of the sensitivity analysis is the robustness of the model. Despite trials with very high
values for k2, the fastest path to somatic cancer is always via a mutation in D then R then A then G, except in
the case where we flip the D:R importance ratio. As expected, a ratio of 0.3:0.7 flips the roles of D and R in the
fastest path to give RDAG, but does not change the time to 1012 M cells from the default value of 51.75 years.
Using a D:R ratio of 0.8:0.2 decreases the time to reach 1012 M cells due to the increased weight given to D.
The parameter that has the largest effect on time to reach 1012 M cells is the tumor volume doubling time. A
tumor volume doubling time of 300 days decreases the time to reach 1012 M cells by 13.50 years relative to the
default of 500 days, and a tumor volume doubling time of 700 days increases the time to reach 1012 M cells by
13.00 years. This effect is seen in Figure 4(a) as well as in Table 2. The large effect of this parameter on the
model is due to its impact on the
(
1
b
− 1
d
)
term; when cells have mutations in R and/or D, the terms become
1/bR and/or 1/dD, allowing the cell populations to increase at a rate that reflects the tumor volume doubling
time chosen.
Variations in the birth and death rates to 1 every 5 days and 1 every 30 days also have an effect on time to reach
1012 M cells. This can be seen in row one of Table 2, but the effect is small when compared with the effect of
tumor volume doubling time.
The time (51.75 years) to reach 1012 M cells does not change in varying the percentage of A cells needed to
remove the angiogenesis cap from 0% to 31%. Between 31% and 35%, the time to reach 1012 M cells increases
rapidly. The time (57.50 years) to reach 1012 M cells does not change in varying the percentage from 35% to
100%. This effect can be seen in Figure 4(b). At 31%, the requirement for mutations in the A category begins to
have an effect on the growing cell populations. At 35% and above, the percentage of A cells required is so large
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that sum of the populations of non-normal, non-metastatic cells never gets above 106 because there are never at
least 35% with A mutations. Thus the time to reach 1012 M cells depends only on a fixed number of T cells in
each case, and remains constant at 57.50 years for percentages 35% and above.
A ten-fold change (from 10−7 to 10−6 mutations/gene/cell division) in mutation rate without a G mutation (k1)
has a larger effect on time to reach 1012 M cells than a ten-fold change (from 10−4 to 10−3 mutations/gene/cell
division) in mutation rate with a G mutation (k2). This is due to the fact that the effect of k2 only becomes
important later in tumorigenesis since G is last in the fastest path to cancer, whereas the effect of k1 occurs
at the beginning. There is no change in time to reach 1012 M cells when k2 is increased from 10
−3 to 10−2
mutations/gene/cell division because the effect of mutation rate has already saturated the system at a k2 value
of 10−3.
Increasing the number of genes involved in the transitions decreases time to reach 1012 M cells simply due to
the larger numerator in the differential equations.
Table 2. Sensitivity of the model to changes in changes in parameters. Cell birth and death rates have units days−1. Tumor volume
doubling times are measured in days. Mutation rates are measured as mutations/gene/cell division. Number of genes involved in
transitions are listed as number involved in single, double, triple transitions. “Other” refers to different values tested in the sensitivity
analysis. “Time” refers to age at acquisition of 1012 M cells for a variation in that parameter, measured in years. “Path” refers to
the fastest path to cancer for a variation in that parameter.
Parameter Default Time Path Other Time Path Other Time Path
Cell birth and death rates 1/10 51.75 DRAG 1/5 50.25 DRAG 1/30 54.75 DRAG
Tumor volume doubling time 500 51.75 DRAG 300 38.25 DRAG 700 64.75 DRAG
% A cells needed to remove cap 10% 51.75 DRAG 30% 51.75 DRAG 40% 57.50 DRAG
D : R importance ratio 0.7:0.3 51.75 DRAG 0.8:0.2 50.50 DRAG 0.3:0.7 51.75 RDAG
Mut. rate with a G mutation 10−4 51.75 DRAG 10−3 50.50 DRAG 10−2 50.50 DRAG
Mut. rate without a G mutation 10−7 51.75 DRAG 10−6 48.50 DRAG
# of genes involved in transitions 100, 10, 1 51.75 DRAG 500, 100, 10 48.25 DRAG
(a) (b)
Figure 4. Sensitivity of the model to changes in parameters. (a) Sensitivity to changes in tumor volume doubling time. Time
to reach 1012 M cells is shown for tumor volume doubling times of 300 days, 500 days, and 700 days. (b) Effect of variations in
percentage of A cells required to induce angiogenesis on time to reach 1012 M cells.
8 Discussion
This paper explores facets of the multistep model of oncogenesis. The key findings of this paper are (1) the
fastest path to somatic cancer is predicted to be through gaining mutations in D, then R, then A, then G, (2)
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of the four categories of mutations, inheriting a mutation in G is predicted to produce cancer at the earliest age,
and (3) the fastest path to somatic cancer is robust to realistic changes in parameters, with the model being
most affected by variations in tumor volume doubling time.
The strength of our model lies not in its utility for predicting any one individual’s time to cancer onset per se, but
rather in the fact that it presents a novel approach to understanding the genetic basis of cancer from a systems
biology perspective. Although a thorough testing of this model is not currently possible due to lack of appropriate
biological data, this model establishes the groundwork for future models that can be directly tied to clinical and
molecular data. We hope that the creation of this model for the multistep progression to cancer will encourage
biologists to gather quantitative data and will suggest which experiments should be performed with highest
priority. The only parameter values which are reasonably agreed upon in the literature are the spontaneous
mutation rate and the size to which a tumor can grow before angiogenesis is required. All other parameter values
could use experimental refinement, especially tumor volume doubling time, since it has the largest effect on time
to cancer onset. Better estimates of parameter values, inclusion of two additional categories to give a total of six
steps in the multistep model, and consideration of the role of the immune system in curbing the growth of a tumor
will allow our model to be more appropriately scaled to human cancers. Modeling the multistep accumulation
of genetic mutations in cancer will give insight into topical questions about the progression of a normal cell to
a cancerous cell, enabling cancer treatments to be better targeted to various stages of cancer progression, and
suggesting the most important directions for future experimental research.
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